Luca Gambini
Luca is ranked by Chambers Europe 2023 for Corporate/M&A: Mid Market (Up and coming), by The Legal 500 EMEA 2022 as a “Next Generation Partner” for Healthcare and Life Sciences and by Who’s Who Legal as “Recommended” in the Life Sciences 2022 (Transactional), the M&A 2022 and the Italy 2022 (Life Sciences and M&A and Governance chapters) guides.
He focuses his practice in domestic and cross border M&A, private equity and venture capital transactions acting for investors and companies at all stages of development across the spectrum of life sciences and technology industries, including biotechnology, medical devices, pharmaceutical, and digital/information technology.
He has also gained a strong and extensive experience on commercial contracts for clients operating in the Life Sciences industries, including the drafting and negotiation of pharmaceutical products’ manufacturing, supply, distribution and co-marketing contracts, as well as clinical trials and proctoring agreements, and other commercial and IT agreements.
Luca contributes regularly to newsletters and journals on M&A and Life Sciences topics; he authored the articles “Pros And Cons of Earn-Out Construct in Life Sciences Merger and Acquisition Transactions” and “How to survive to financial crisis, political changes and other adverse events: an overview of MAC clauses in recent transactions with an in-depth analysis of the Abbott Laboratories/Alere Inc. case” (both articles published by Bocconi Legal Papers), and he co-authored the Italian chapter of The Life Sciences Law Review and contributed to the ABA European Private Target M&A Deal Points Study 2017.
Prior to joining the firm he completed an internship with a law firm in Washington DC and he has been on secondment at the M&A and Private Equity department of Morrison & Foerster LLP in New York City, assisting some of the main US and Canadian private equity funds.
He graduated in 2006 from the Luiss Guido Carli of Roma.
Foreign languages: English
Luca is a member of the Rome Bar Association.
-
26 February 2021Foreign investment control regulations: extension of COVID-19–related rules and new list and definition of strategic assets with a brief focus on the health industry
-
15 October 2020Foreign investment control in the life science sector: the scope of the Italian Government’s powers also in the context of the current COVID-19 pandemic
-
19 June 2020Patient Support Program in digitale, come farlo bene e a norma
-
11 June 2020Acquisitions of companies involved in the medical devices business fall under the Italian foreign investment control
